The existence of a proprietary patented process speaks to the “willfulness” (i.e. the lack thereof) of NVS/MNTA’s infringement in the event the Judge finds that NVS/MNTA’s generic Copaxone does infringe.
When was the last time treble damages were assessed in a generic-drug case? I’m not sure if it’s ever happened.
Market Data 
Markets 
AI
